The role of tetramerization in p53 function

The tumour suppressor gene p53 is extensively studied for its importance in cancer. In its active conformation, p53 is tetrameric and one domain – the tetramerization domain – permits the oligomerization of this protein. Until recently, little attention was given to this domain because, in contrast to the DNA-binding domain, it is not often mutated in cancer. However, various experimental studies have shown evidence that the tetramerization domain is essential for DNA binding, protein–protein interactions, post-translational modifications, and p53 degradation. Moreover, single mutations in the tetramerization domain can inactivate the wild-type protein in a manner similar to that seen with mutations in the DNA-binding domain. Interestingly, the phenotype of several tetramerization domain mutants differs from that observed with DNA-binding domain mutants. In this review, current knowledge about the importance of the tetramerization domain to the function of p53 will be summarized.

[1]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[2]  C. Arrowsmith,et al.  Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. , 1995, Biochemistry.

[3]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[4]  T. Davison,et al.  Characterization of the oligomerization defects of two p53 mutants found in families with Li–Fraumeni and Li–Fraumeni-like syndrome , 1998, Oncogene.

[5]  E. Appella,et al.  Signaling to p53: breaking the posttranslational modification code. , 2000, Pathologie-biologie.

[6]  P. Chène,et al.  Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties. , 1999, Journal of molecular biology.

[7]  M. Grütter,et al.  Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. , 1998, Acta crystallographica. Section D, Biological crystallography.

[8]  K. McLure,et al.  How p53 binds DNA as a tetramer , 1998, The EMBO journal.

[9]  J. Garin,et al.  The in vitro phosphorylation of p53 by calcium-dependent protein kinase C--characterization of a protein-kinase-C-binding site on p53. , 1997, European journal of biochemistry.

[10]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[11]  A. Gronenborn,et al.  The oligomerization domain of p53: Crystal structure of the trigonal form , 1996, FEBS letters.

[12]  T. Halazonetis,et al.  The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.

[13]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[14]  K. Vousden,et al.  Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.

[15]  D. Simmons,et al.  Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site. , 1988, Virology.

[16]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[17]  C Béroud,et al.  p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.

[18]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[19]  M. Malanga,et al.  Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions* , 1998, The Journal of Biological Chemistry.

[20]  T. Halazonetis,et al.  Wild‐type p53 adopts a ‘mutant’‐like conformation when bound to DNA. , 1993, The EMBO journal.

[21]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[22]  K. McLure,et al.  p53 DNA binding can be modulated by factors that alter the conformational equilibrium , 1999, The EMBO journal.

[23]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Vidal,et al.  Dominant-negative p53 mutations selected in yeast hit cancer hot spots. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Davison,et al.  p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.

[26]  P. Tegtmeyer,et al.  Interaction of p53 with its consensus DNA-binding site , 1995, Molecular and cellular biology.

[27]  V. Zhurkin,et al.  p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Levine,et al.  Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.

[29]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[30]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[31]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[32]  J. E. Stenger,et al.  p53 oligomerization and DNA looping are linked with transcriptional activation. , 1994, The EMBO journal.

[33]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[34]  M. Blagosklonny,et al.  p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  T. Yamashita,et al.  The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. , 1997, Cancer research.

[36]  N. Horikoshi,et al.  Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor , 1996, Science.

[37]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[38]  H. Sakamoto,et al.  Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Hollstein,et al.  p53 and human cancer: the first ten thousand mutations. , 2000, Advances in cancer research.

[40]  A. Levine,et al.  The Spectrum of Mutations at the p53 Locus , 1995, Annals of the New York Academy of Sciences.

[41]  C. Surridge Forewarned is four-armed , 1994, Nature.

[42]  P. Slootweg,et al.  Gain-of-function mutations in the tumor suppressor gene p53. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  A M Gronenborn,et al.  Interhelical angles in the solution structure of the oligomerization domain of p53: correction , 1995, Science.

[44]  K. Wiman,et al.  p53: a cell cycle regulator activated by DNA damage. , 1995, Advances in cancer research.

[45]  V. Rotter,et al.  Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.

[46]  G. Marius Clore,et al.  Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.

[47]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[48]  R. Camplejohn,et al.  Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members , 1998, Oncogene.

[49]  X. Sun,et al.  p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. , 2000, Biochemical and biophysical research communications.

[50]  H. Sakamoto,et al.  Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. , 1997, Biochemistry.

[51]  A. Fersht,et al.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain , 1998, The EMBO journal.

[52]  P. Friedman,et al.  The p53 protein is an unusually shaped tetramer that binds directly to DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Chène,et al.  p53 mutants without a functional tetramerisation domain are not oncogenic. , 1999, Journal of molecular biology.

[54]  J. Varley,et al.  Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family , 1997, Oncogene.

[55]  D. Meek,et al.  Mechanisms of switching on p53: a role for covalent modification? , 1999, Oncogene.

[56]  E. Stavridi,et al.  Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions , 1999, Protein science : a publication of the Protein Society.

[57]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[58]  C. Maki Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2* , 1999, The Journal of Biological Chemistry.

[59]  Xuan Liu,et al.  Stimulation of p53 DNA Binding by c-Abl Requires the p53 C Terminus and Tetramerization , 2000, Molecular and Cellular Biology.

[60]  D. Pim,et al.  Interaction between the HPV-16 E2 transcriptional activator and p53 , 1999, Oncogene.

[61]  P. Chène Influence of the N-terminal region on the oligomerisation between human and Xenopus laevis p53. , 1999, Journal of molecular biology.

[62]  T. Halazonetis,et al.  Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. , 1993, The EMBO journal.

[63]  P. Hainaut,et al.  New approaches to understanding p53 gene tumor mutation spectra. , 1999, Mutation research.

[64]  R. Tjian,et al.  SV40 T antigen binds specifically to a cellular 53 K protein in vitro , 1981, Nature.

[65]  P. Y. Chou,et al.  Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. , 1974, Biochemistry.

[66]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[67]  Alan R. Fersht,et al.  Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53 , 1999, Nature Structural Biology.

[68]  K. Roemer,et al.  Function, oligomerization, and conformation of tumor‐associated p53 proteins with mutated C‐terminus , 2000, Journal of cellular biochemistry.

[69]  O. Halevy,et al.  Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment , 1989, Molecular and cellular biology.

[70]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[71]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[72]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[73]  J. Milner,et al.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation , 1991, Cell.

[74]  J. E. Stenger,et al.  Formation of stable p53 homotetramers and multiples of tetramers , 1992, Molecular carcinogenesis.

[75]  P. Chène,et al.  Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain , 1998, International journal of cancer.

[76]  E. Shaulian,et al.  Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. , 1993, The EMBO journal.

[77]  M. Hixon,et al.  Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint. , 2000, Histology and histopathology.

[78]  J. E. Stenger,et al.  p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.

[79]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[80]  A. Fersht,et al.  Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Grütter,et al.  In vitro structure-function analysis of the beta-strand 326-333 of human p53. , 1997, Journal of molecular biology.

[82]  R. Kanamaru,et al.  Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. , 1997, Biochemical and biophysical research communications.

[83]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[84]  J. Milner,et al.  Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. , 1990, Journal of molecular biology.

[85]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[86]  P. Chène In vitro analysis of the dominant negative effect of p53 mutants. , 1998, Journal of molecular biology.

[87]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[88]  M. Oren,et al.  Oligomerization of oncoprotein p53 , 1988, Journal of virology.

[89]  K. Roemer Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators , 1999, Biological chemistry.